Overview

The 6Wresearch India Export Attractiveness Tracker 2026 forecasts that India’s total export opportunity will reach $94.5 billion by 2031. The single largest export segment is smartphones, projected at $35.9 billion.

Current Export Landscape

  • Existing top‑five importing countries together account for $413.5 billion of current export potential: United States $213.68 billion (27%), China $79.48 billion (10%), Hong Kong $51.79 billion (7%), Japan $43.51 billion, and Canada $27.45 billion.
  • New‑potential markets (where India has minimal current trade) represent $30.1 billion of untapped opportunity. Japan leads this cohort with $3.71 billion (12.32%), followed by the United States $3.35 billion (11.14%), China $3.10 billion (10.30%), Mexico $2.90 billion (9.62%), and Vietnam $0.96 billion (3.18%).

Emerging Product Opportunities

  • Iron‑Ore Concentrates (Non‑Agglomerated): total potential $3.65 billion, with Japan alone at $2.33 billion; Bahrain $518.33 million, Oman $406.91 million, Vietnam $211.24 million, Turkey $89.10 million.
  • Light Commercial Vehicles (LCV – Gasoline): potential $1.63 billion, United States contributing $1.5 billion; other contributors Canada, Mexico, Guatemala, Australia.
  • Light Petroleum Oils: potential $1.5 billion, led by Mexico $878 million.
  • Additional niche opportunities: Gasoline Passenger Cars (1.5–3.0 L) $1.17 billion (China $746 million), Agglomerated Iron‑Ore Concentrates $679 million (Egypt $274 million).

Core High‑Value Export Segments

  • Smartphones: $35.9 billion, dominated by the United States.
  • Polished Diamonds: $58.2 billion, with the United States $19.3 billion, Hong Kong $15.1 billion, UAE $7.9 billion.
  • Refined & Light Petroleum Oils: combined $44.7 billion, led by the United States and Singapore.
  • Medicines (Generic): $23.3 billion, United States $8.67 billion, Switzerland $3.15 billion, China $1.81 billion, Japan $1.45 billion, Canada $758.62 million.
  • The broader pharmaceuticals sector totals $66.81 billion, with the United States accounting for $20.13 billion (≈30%).

Tariff Landscape

  • Japan offers duty‑free access for non‑agglomerated iron‑ore concentrates.
  • United States LCV (Gasoline) previously faced 25% duty; the India‑US Interim Trade Agreement (Feb 2026) reduced baseline tariff to 10% with a roadmap for further reduction.
  • Mexico provides 0% tariff on light petroleum oils.
  • China applies 15% tariff on gasoline passenger cars, reduced to 13.5% under APTA preferences.
  • Egypt grants 0% duty on agglomerated iron‑ore concentrates.

Regulatory Environment

  • Near‑zero tariffs now mask dense non‑tariff measures: the United States imposes 213 regulatory measures on medicines and 49 on refined petroleum oils; China has 148 measures on medicines; the UAE applies 20 measures on light petroleum oils and 13 on polished diamonds.
  • Preferential agreements (India‑UAE CEPA, India‑Singapore CECA) eliminate duties on polished diamonds and light petroleum oils for qualifying trade.

Semiconductor Outlook

  • Global export opportunity for electronic integrated circuits alone is $685.7 billion, with refined petroleum oils ($668.4 billion) and light petroleum oils ($588.9 billion) also prominent.
  • India’s semiconductor play focuses on assembly, packaging, testing, EMS and advanced manufacturing, supported by government incentives and rising AI‑driven demand.

Current Trade Anchors (2026 data)

  • Oil & Gas: $69.07 billion (71.4% refined petroleum, 28.6% light petroleum).
  • Telecommunications Equipment: $23.20 billion, 86.8% smartphones.
  • Pharmaceuticals: $32.56 billion, 54.1% medicines.
  • Top destination markets: United States $79.4 billion (medicines 9.6%, smartphones 8.8%); United Arab Emirates $37.1 billion (precious‑metal jewelry 13.4%, light petroleum oils 10.1%); Netherlands $24.2 billion (refined petroleum oils 61.3%).

Risk Highlight – U.S. Generic Drug Tariff

  • On July 21 2026, the United States announced a phased tariff on generic medicines: 0% through July 2028, 100% for one year, then 200% from August 2029. India supplies roughly 40–47% of U.S. generic prescriptions (≈ $9.7 billion today). The two‑year duty‑free window shields near‑term sales, but the eventual 200% tariff poses a material risk to the $23.3 billion pharma export outlook.

Bottom Line

India’s next export wave will be driven by scaling in zero‑tariff corridors (Japan, Egypt, Mexico) while investing early in regulatory compliance for high‑value markets (U.S., China, UAE). Capturing the $30.1 billion of untapped potential will require simultaneous capacity expansion and standards alignment.